Development of second generation epigenetic agents

This hot review from Philip Jones, MD Anderson Cancer Center, Texas, examines our understanding of the structure and function of epigenetic enzymes, including lysine and arginine methyltransferases and demethylases, histone acetyl transferases and histone deacetylases, and the chemical probes and tools available to increase our understanding.

It focuses on the development of a second generation of epigenetic agents able to manipulate histone modifications responsible for aberrant epigenetic gene transcription associated with disease states.

Areas covered:

  • Class I and II HDAC inhibitors
  • HDAC 1-4, 6, 8 selective inhibitors
  • Class III HDAC inhibitors
  • Histone acetyl transferase inhibitors
  • Histone methyltransferase inhibitors
  • Lysine and arginine methyltransferase inhibitors
  • Histone demethylase inhibitors
  • Lysine specific demethylase 1 inhibitors
  • JmJ demethylase inhibitors

Development of second generation epigenetic agents
Philip Jones
DOI: 10.1039/C1MD00199J

This article is part of our forthcoming themed issue on Epigenetics – check back soon for more hot articles in this issue!

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

HOT: A self-immolative strategy to enhance cancer chemotherapy selectivity

In this Hot article, scientists from France present a self-immolative dendritic glucuronide prodrug designed for the release of two doxorubicin molecules after a single triggering event.

‘While numerous glucuronide prodrugs have been studied so far, the efficiency of this targeting strategy is limited by the poor turnover of beta-glucuronidase in malignant tissues. Our novel dendritic prodrug which is programmed to release two molecules of doxorubicin after a single enzymatic activation step may permit to overcome this drawback’, the authors explain.

The biological experiments conducted have shown that this novel enzyme-responsive dendritic prodrug is twice more toxic than its monomeric counterpart against H661 lung cancer cells. It is hoped that this novel approach may open new avenues in selective cancer chemotherapy.

Selected as HOT, read this article for free now.

A self-immolative dendritic glucuronide prodrug of doxorubicin
Marion Grinda, Jonathan Clarhaut, Brigitte Renoux, Isabelle Tranoy-Opalinski and Sébastien Papot
Med. Chem. Commun., 2011, Advance Article
DOI: 10.1039/C1MD00193K, Concise Article

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

HOT: acetylphosphonates inhibit DXP synthase in the MEP pathway

This hot article from Caren Freel Meyers and coworkers describes new inhibitors of DXP synthase, which catalyse an important precursor in the pathogen MEP pathway to isoprenoids.  Butylacetylphosphonate was able to selectively inhibit E. coli DXP synthase.

Selective inhibition of E. coli 1-deoxy-D-xylulose-5-phosphate synthase by acetylphosphonates
Jessica M. Smith, Ryan J. Vierling and Caren Freel Meyers
Med. Chem. Commun., 2012, Advance Article
DOI: 10.1039/C1MD00233C

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

New antimalarial compounds: the class of 2011

In another step to overcome bacterial resistance to antibiotics, scientists from India have made a new class of triazines. Sixteen compounds showed excellent activity against malaria, say the researchers, preserving the potency of their parent antimalarial drug chloroquine. IC50 values ranged from 1.36 to 4.63ng ml-1.

Synthesis of hybrid 4-anilinoquinoline triazines as potent antimalarial agents, their in silico modeling and bioevaluation as Plasmodium falciparum transketolase and β-hematin inhibitors
Moni Sharma, Kuldeep Chauhan, Shikha S. Chauhan, Ashok Kumar, Shiv Vardan Singh, Jitendra K. Saxena, Pooja Agarwal, Kumkum Srivastava, S. Raja Kumar, Sunil K. Puri, Priyanka Shah, M. I. Siddiqi and Prem M. S. Chauhan
DOI: 10.1039/C1MD00188D

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

Tracking immune cell migration on the cover of Issue 11

On the cover of Issue 11 is a hot article from Mark Bradley and coworkers on a method to track innate immune cell migration in vivo using dye-labelled peptoids.

Far red and NIR dye-peptoid conjugates for efficient immune cell labelling and tracking in preclinical models
Kevin Dhaliwal, Géraldine Escher, Asier Unciti-Broceta, Neil McDonald, A. John Simpson, Chris Haslett and Mark Bradley
Med. Chem. Commun., 2011, 2, 1050-1053
DOI: 10.1039/C1MD00171J

Also in this issue is Ying-Wei Yang’s review on biocompatible nanovalves for drug delivery and release:

Towards biocompatible nanovalves based on mesoporous silica nanoparticles
Ying-Wei Yang
Med. Chem. Commun., 2011, 2, 1033-1049
DOI: 10.1039/C1MD00158B

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

Hot Perspective: Reviewing current knowledge on DNA methylation aspects

In this MedChemComm article*, Nadine Martinet and colleagues at the Universities of Nice-Sophia Antipolis and Poitiers (France) provide a timely overview of the current knowledge concerning DNA methyltransferases (DNMT) biology and the two main classes of DNMT inhibtors, also highlighting epigenetic anti-cancer therapeutic strategies.

Read the article for FREE for the next 4 weeks!

Small molecules DNA methyltransferases inhibitors
Nadine Martinet, Benoît Y. Michel, Philippe Bertrand and Rachid Benhida
Med. Chem. Commun., 2011, Advance Article
DOI: 10.1039/C1MD00194A, Review

*This article will be part of MedChemComm’s web theme issue on Epigenetics, coming soon.

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

New compound class for treating hepatitis C virus

Researchers from Biotica, UK have discovered a new compound class called sangamides with the potential to treat hepatitis C.   Sangamides are amide derivatives of sanglifehrin A – a cyclophilin-binding polyketide natural product.  Non-immunosuppressive analogues of sanglifehrin A are currently under development as hepatitis C virus therapies, but suffer from lengthy synthetic processes, and some adverse affects including drug-drug interactions.

The newly developed sangamides display improved potency and good pharmcokinetic properties that make them potentially suitable for once-a-day oral treatment of chronic hepatitis C infection.  Download the article for the full details:

Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV infection
Steven J. Moss, Michael Bobardt, Pieter Leyssen, Nigel Coates, Udayan Chatterji, Xie Dejian, Teresa Foster, Jinlun Liu, Mohammad Nur-e-Alam, Dipen Suthar, Chen Yongsheng, Tony Warneck, Ming-Qiang Zhang, Johan Neyts, Philippe Gallay, Barrie Wilkinson and Matthew A. Gregory
Med. Chem. Commun., 2012, Advance Article
DOI: 10.1039/C1MD00227A

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

Top ten accessed articles in September

This month sees the following articles in MedChemComm that are in the top ten most accessed:

2-Anilinonicotinyl linked 1,3,4-oxadiazole derivatives: Synthesis, antitumour activity and inhibition of tubulin polymerization
Ahmed Kamal, Y. V. V. Srikanth, Thokhir B. Shaik, M. Naseer A. Khan, Md. Ashraf, M. Kashi Reddy, K. Anil Kumar and Shasi V. Kalivendi
Med. Chem. Commun., 2011, 2, 819-823
DOI: 10.1039/C0MD00177E

Towards biocompatible nanovalves based on mesoporous silica nanoparticles
Ying-Wei Yang
Med. Chem. Commun., 2011, Advance Article
DOI: 10.1039/C1MD00158B

Minisci reactions: Versatile CH-functionalizations for medicinal chemists
Matthew A. J. Duncton
Med. Chem. Commun., 2011, Advance Article
DOI: 10.1039/C1MD00134E

Molecular obesity, potency and other addictions in drug discovery
Michael M. Hann
Med. Chem. Commun., 2011, 2, 349-355
DOI: 10.1039/C1MD00017A

Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space
Alexander Alex, David S. Millan, Manuel Perez, Florian Wakenhut and Gavin A. Whitlock
Med. Chem. Commun., 2011, 2, 669-674
DOI: 10.1039/C1MD00093D

The development of quinolone esters as novel antimalarial agents targeting the Plasmodium falciparum bc 1 protein complex
Robin Cowley, Suet Leung, Nicholas Fisher, Mohammed Al-Helal, Neil G. Berry, Alexandre S. Lawrenson, Raman Sharma, Alison E. Shone, Stephen A. Ward, Giancarlo A. Biagini and Paul M. O′Neill
Med. Chem. Commun., 2012, Advance Article
DOI: 10.1039/C1MD00183C

Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes
Jeffrey A. Pfefferkorn, Angel Guzman-Perez, Peter J. Oates, John Litchfield, Gary Aspnes, Arindrajit Basak, John Benbow, Martin A. Berliner, Jianwei Bian, Chulho Choi, Kevin Freeman-Cook, Jeffrey W. Corbett, Mary Didiuk, Joshua R. Dunetz, Kevin J. Filipski, William M. Hungerford, Christopher S. Jones, Kapil Karki, Anthony Ling, Jian-Cheng Li, Leena Patel, Christian Perreault, Hud Risley, James Saenz, Wei Song, Meihua Tu, Robert Aiello, Karen Atkinson, Nicole Barucci, David Beebe, Patricia Bourassa, Francis Bourbounais, Anne M. Brodeur, Rena Burbey, Jing Chen, Theresa D’Aquila, David R. Derksen, Nahor Haddish-Berhane, Cong Huang, James Landro, Amanda Lee Lapworth, Margit MacDougall, David Perregaux, John Pettersen, Alan Robertson, Beijing Tan, Judith L. Treadway, Shenping Liu, Xiayang Qiu, John Knafels, Mark Ammirati, Xi Song, Paul DaSilva-Jardine, Spiros Liras, Laurel Sweet and Timothy P. Rolph
Med. Chem. Commun., 2011, 2, 828-839
DOI: 10.1039/c1md00116g

Discovery of CP-866,087, a mu opioid receptor antagonist for the treatment of alcohol abuse and dependence
Stanton F. McHardy, Steven D. Heck, Sara Guediche, Monica Kalman, Martin P. Allen, Meihua Tu, Dianne K. Bryce, Anne W. Schmidt, Michelle Vanase-Frawley, Ernesto Callegari, Shawn Doran, Nicholas J. Grahame, Stafford McLean and Spiros Liras
Med. Chem. Commun., 2011, 2, 1001-1005
DOI: 10.1039/C1MD00164G

Synthesis and evaluation of novel 5-sulfonyl-indolin-2-ones as potent cytotoxic agents
Yu Luo, Feng Xiao, Shijing Qian, Qiaojun He, Wei Lu and Bo Yang
Med. Chem. Commun., 2011, Advance Article
DOI: 10.1039/C1MD00105A

Design, synthesis and antiproliferative activity of urocanic-chalcone hybrid derivatives
Alexander Ciupa, Natalie J. Griffiths, Stephanie K. Light, Pauline J. Wood and Lorenzo Caggiano
Med. Chem. Commun., 2011, 2,1011-1015
DOI: 10.1039/C1MD00155H

Why not take a look at the articles today and blog your thoughts and comments below.

Fancy submitting an article to MedChemComm? Then why not submit to us today or alternatively email us your suggestions.

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

Current progress in inhibiting Stat5 protein signalling

This mini-review from Patrick Gunning et al. looks at progress made towards inhibiting Stat5, a member of the Stat family of signalling proteins, that is connected to many cancers, including acute myeloid leukemias and prostate cancer.

Areas covered include both direct and indirect inhibition:

  • Bcr/Abl inhibitors
  • FLT3 inhibitors
  • Jak2 inhibitors
  • truncation inhibitors
  • Binding to DNA
  • Disrupting dimerisation

Inhibitors of Stat5 protein signalling
Abbarna A. Cumaraswamy, Aleksandra Todic, Diana Resetca, Mark D. Minden and Patrick T. Gunning
Med. Chem. Commun., 2011, Advance Article
DOI: 10.1039/C1MD00175B

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

Poster prize winner at the 16th SCI/RSC Medicinal Chemistry Symposium

I am delighted to report that Dr Martine Keenan from Epichem Pty Ltd (Murdoch, Australia) was the winner of the MedChemComm poster prize at the recent 16th SCI/RSC Medicinal Chemistry Symposium that took place at Churchill College in Cambridge, UK, from 11 to 14 September.

The symposium was jointly organised by the Society of Chemical Industry and the Royal Society of Chemistry, and gave a splendid overview of some of the new strategies in Medicinal Chemistry and Pharmaceutical Research.

Martine’s winning poster entitled ‘Collaborative drug discovery for neglected diseases: novel compounds for the treatment of Chagas Disease’ presents the identification and development of two novel compound series active against the intracellular protozoan parasite Trypanosoma cruzi, the causative agent of the Chagas disease. Endemic in 21 countries across Latin America, the Chagas disease is responsible for more deaths in this region than Malaria, or any other parasite-born disease, and is currently spreading to developed countries including Australia, USA, Japan or Spain. This award winning work is the result of a collaborative drug discovery consortium established by not-for-profit, drug research and development organisation Drugs for Neglected Diseases initiative (DNDi).

Congratulations again to Martine on her award-winning work and to the collaborative drug delivery consortium for their active research on neglected diseases.

    Keep up to date with the latest news and research in medicinal chemistry: sign up to the MedChemComm e-alert, check out our blog, and follow us on Twitter.

    Digg This
    Reddit This
    Stumble Now!
    Share on Facebook
    Bookmark this on Delicious
    Share on LinkedIn
    Bookmark this on Technorati
    Post on Twitter
    Google Buzz (aka. Google Reader)